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Background: Inert nanoparticles are attracting attention as carriers for protein-based vaccines. Here we evaluate
the immunogenicity of the model antigen ovalbumin delivered on polystyrene particles and directly compare
particulate delivery with adenovirus-based immunization.
Findings: Mice were vaccinated with soluble ovalbumin, ovalbumin-coated polystyrene particles of different sizes,
or an adenovirus-based expression-display vector that encodes and displays a pIX-ovalbumin fusion protein.
Antibody responses were clearly higher when ovalbumin was administered on polystyrene particles compared to
soluble protein administration, regardless of the particle size. Compared to adenovirus-based immunization,
antibody levels were lower if an equivalent amount of protein was delivered, and no cellular immune response was
detectable.
Conclusions: We demonstrate in a side-by-side comparison that inert nanoparticles allow for the reduction of the
administered antigen amount compared to immunization with soluble protein and induce strongly enhanced
antibody responses, but responses are lower compared to adenovirus-based immunization.
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Protein and peptide vaccines are generally regarded as
safe; however, in most cases they require the co-
administration of adjuvants to be effective, which may
in turn cause adverse events [1]. Therefore it is desirable
to develop safe and clinically effective non-adjuvanted
vaccines, and one approach is the use of nano- or micro-
particles coated with antigen, which can enhance im-
munogenicity compared to soluble antigen [2-4]. In this
study we analyzed polystyrene particles coated with the
model antigen ovalbumin for their potency at inducing
humoral and cellular responses. As adenoviral (Ad) vec-
tors are very popular for vaccine development because of
their high immunogenicity and strong immune responses* Correspondence: wibke.bayer@uni-due.de
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reproduction in any medium, provided the orto the delivered vaccine antigens, we made side-by-side
comparisons of coated polystyrene particles of varying
sizes with an Ad expression-display vector, which we
showed before to induce especially good CD4+ T cell
and antibody responses [5].
Carboxyl-modified polystyrene beads of 24, 60, 93,
220 and 340 nm in diameter (BangsLabs/Polysciences,
Fishers, IN) were loaded with recombinant ovalbumin
(Sigma, Munich, Germany) by the carbodiimide method
[6], and antigen loading was verified by dot blot and
enzyme-linked immunosorbent assay (ELISA; data
not shown). For immunization experiments, 8–9 weeks
old C57BL/6 mice (Élevage Janvier, Le Genest St Isle,
France) were used. Mice were treated in accordance
with the regulations and guidelines of the Institutional
Animal Care and Use Committee of the Ruhr University
Bochum, Germany.
To determine the best route of administration for
particle-based immunization, mice received 5 μg ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.virologyj.com/content/10/1/108soluble ovalbumin or ovalbumin loaded on polystyrene
particles diluted in 100 μl sterile PBS by intramuscular,
subcutaneous, or intraperitoneal injection, or by intrader-
mal injection into both hind footpads. Ovalbumin-specific
antibody levels were determined two weeks after im-
munization by ELISA [7] using ECL substrate (Alpha
Innotech, San Leandro, USA) for luminometric readout.
Soluble ovalbumin only induced a significant antibody
level after immunization by intramuscular injection, but
not the other routes, whereas all particles induced ovalbu-
min-binding antibodies regardless of the immunization
route (Figure 1A). Antibody levels induced by ovalbumin-
loaded particles were significantly higher than after im-
munization with soluble ovalbumin (Figure 1A). Next, we
analyzed the amount of protein necessary for the induc-
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Figure 1 Immune response after immunization with ovalbumin loade
5 μg soluble ovalbumin (ova), or ovalbumin-coated polystyrene particles of
diameter (340p) carrying 5 μg ovalbumin, either by intramuscular, footpad,
immunization ovalbumin specific IgG levels were determined luminometric
different amounts of protein, mice were immunized once by intramuscular
soluble protein or coated on 93 nm polystyrene particles, and IgG1 (B) and
two weeks after immunization. Statistically significant differences compared
soluble ovalbumin are indicated by * or #, respectively (P < 0.05, Student-N
(relative light units per second) and standard errors of the means of 4 (B, C
independent experiments.immunized once by intramuscular injection with 50 ng,
500 ng, or 5 μg of ovalbumin, either as soluble protein or
coupled to 93 nm polystyrene particles. While 5 μg of sol-
uble ovalbumin were necessary to induce measurable
IgG1 antibody titers, 500 ng on 93 nm particles were suffi-
cient to induce high levels of IgG1 (Figure 1B). Antibodies
of IgG2c subtype were not induced in detectable amounts
by either vaccination strategy (Figure 1C).
To analyze whether the induction of antibodies by
protein-loaded polystyrene particles is dependent on
CD4+ T cell help, mice were immunized twice with 93
nm polystyrene particles delivering the intermediate
amount of 500 ng ovalbumin, and depleted of CD4+ T
cells around both time points of immunization by intra-
peritoneal injection of a CD4 antibody [8]. After mice
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d polystyrene particles. C57BL/6 mice were immunized once with
24 nm (24p), 60 nm (60p), 93 nm (93p), 220 nm (220p), or 340 nm
subcutaneous or intraperitoneal injection. Two weeks after
ally from 1:10000 dilutions of plasma by ELISA (A). To compare
injection with 50 ng, 500 ng, or 5000 ng of ovalbumin, either as
IgG2c antibody titers (C) were analyzed in 1:100 dilution of plasma
to naïve mice or mice immunized with the respective amount of
ewman-Keuls method). The graphs show mean values of RLU/s
) or 8 mice per group (A); data was acquired in two
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http://www.virologyj.com/content/10/1/108antibodies were detectable (data not shown), suggesting
the necessity of CD4+ T cell help for antibody induction.
Adenoviral vectors are very popular tools for vaccine
development and they are known to be highly immuno-
genic [9]. We compared immune responses induced by
polystyrene particles loaded with ovalbumin with an
adenoviral ovalbumin expression-display vector; this
Ad5 vector Ad.pIXova encodes a fusion protein of the
capsid protein IX and ovalbumin, and hence displays ov-
albumin on the particle [5]. The ovalbumin content of
Ad.pIXova was determined by ELISA to be 50 ng per
1010 viral particles (vp; data not shown). To include a
control for the influence of in vivo expression of ovalbu-
min from the adenoviral vector, a UV-inactivated [10]
Ad.pIXova (UV-AdpIXova) was included. Mice were im-
munized twice in a three-week interval by intradermal
injection into the hind footpads with 50 ng soluble ov-
albumin, 50 ng ovalbumin coupled to 24 nm, 93 nm, or





























































































Figure 2 Immune response after immunization with ovalbumin loade
immunized twice by intradermal injection into the hind footpads with 50 n
(24p), 93 nm (93p) or 340 nm diameter (340p) carrying 50 ng ovalbumin, o
Three weeks after boost-immunization, ovalbumin binding IgG1 (A) and Ig
(B). For analysis of cellular immune responses, spleen cells were isolated an
expression by CD8+ (C) and CD4+ T cells (D) was analyzed by flow cytome
immunized with soluble ovalbumin are indicated by * or #, respectively (P
8 mice per group that was acquired in two independent experiments, theUV-AdpIXova, equaling a protein delivery of 50 ng ov-
albumin; immune responses were analyzed three weeks
after the second immunization.
Immunization of mice with active or inactivated ade-
noviral vectors resulted in detectable levels of both IgG1
and IgG2c type ovalbumin-binding antibodies (Figure 2A
and B). While the immunization with 50 ng soluble ov-
albumin did not induce detectable antibodies of either
subtype, mice immunized with polystyrene particles car-
rying the same amount of ovalbumin exhibited binding
antibody responses of mainly IgG1 type, with the highest
response in mice immunized with 93 nm particles,
which showed levels similar to mice immunized with
UV-AdpIXova.
For the analysis of cellular immune responses, sple-
nocytes were isolated and restimulated in vitro with
ovalbumin-derived peptides [11,12], and flow-cytometric
analysis of intracellular cytokine levels was performed.



























































































d polystyrene particles or adenoviral vectors. C57BL/6 mice were
g soluble ovalbumin, ovalbumin-coated polystyrene particles of 24 nm
r 1010 vp ovalbumin-displaying adenovirus Ad.pIXova or UV-AdpIXova.
G2c antibody levels were analyzed from 1:100 dilutions of plasma
d restimulated in vitro with ovalbumin-specific peptides, and IFNγ
try. Statistically significant differences compared to naïve mice or mice
< 0.05, Student-Newman-Keuls method). The graphs show data of
bars indicate mean values.
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nized with Ad.pIXova, and significantly lower when mice
were immunized with the UV-inactivated UV-AdpIXova
or polystyrene particles carrying 50 ng ovalbumin. While
there is a tendency to higher CD8+ T cell levels in mice
immunized with UV-AdpIXova than polystyrene particles,
the levels are comparable in these groups and underline
the importance of antigen expression by the Ad vector
for strong CTL induction, as well as for induction of
CD4+ T cell responses, as was described before [5]. A
similar trend was observed when the concentration of
IL4 was analyzed in the supernatant of restimulated
splenocytes, although the levels were rather low in all
groups (data not shown).
As no relevant cellular immunity was induced by poly-
styrene particle immunization, we wanted to further as-
sess the immunogenicity of the particles, and analyzed
activation of and interferon production by dendritic cells
(DCs) after uptake of ovalbumin-loaded particles or ade-


















































Figure 3 Activation of dendritic cells by ovalbumin-loaded particles. 5
soluble ovalbumin, polystyrene particles loaded with 10 ng ovalbumin, or w
lipopolysaccharide (LPS) was used as negative and positive controls, respec
activation markers CD80 and CD86 and analyzed by flow cytometry (A). Su
β concentrations (B). Statistically significant differences compared to untreawas observed after loading with the largest, 220 nm and
340 nm polystyrene particles, whereas incubation with
adenoviral particles led to DC activation comparable to
stimulation with LPS (Figure 3A). Adenoviral particles
also induced significant levels of interferon α and inter-
feron β, but DCs incubated with soluble ovalbumin or
ovalbumin-coated polystyrene particles did not produce
interferons (Figure 3B). These findings confirm the inert
nature of the polystyrene particles.
Comparing the immune responses induced by adeno-
virus-based immunization with immune responses in-
duced by polystyrene particles loaded with a high
amount of protein, i.e. 5 μg, it can be observed that the
antibody levels that can be reached by immunization
with protein-coated 93 nm particles are actually compar-
able in strength. It has been reported before that the
particle size determines the induced immune response
(reviewed in [13]), and our findings confirm this, as the
best antibody response was found for the 93 nm parti-








































×105 bone-marrow derived DCs were co-incubated with 10 ng
ith 109 vp Ad.pIXova or UV-AdpIXova. Incubation with medium or
tively. After 16 h co-incubation, cells were stained for expression of the
pernatants of the cells were analyzed by ELISA for interferon α and
ted DCs are indicated by * (P < 0.05, Student-Newman-Keuls method).
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could induce a significant, albeit low, CD8+ T cell re-
sponse (data not shown).
Our results indicate that antigen coupling to polystyr-
ene particles, although they are immunologically inert,
induces enhanced antibody responses in comparison to
immunization with soluble protein, and thus allows for
the reduction of protein amount used for protein-based
immunization. In contrast to adenoviral vectors, delivery
on polystyrene particles does not change the antibody
profile compared to protein immunization, which con-
sists predominantly of IgG1 subtype antibodies.
We confirmed that polystyrene particles themselves
are not immunogenic, having no particular effect on DC
activation and cytokine production, thus they should be
associated with very little risk of inducing autoimmunity
as recently described for other vaccine adjuvants [15]
(and reviewed in [16]). Rather, the enhancing effect of
polystyrene particle delivery seems to rely mainly on the
particulate nature and the size of the particles, as well as
on the presentation of the antigen in an ordered array.
Polystyrene particles are inert but not degradable, how-
ever, biodegradable particles such as dextran particles
should be comparably adequate protein carriers and ap-
propriate for use in humans. While the cellular immune
response to adenoviral vectors was much higher than to
antigen-coated polystyrene particles, in cases where pro-
tection can be conferred by humoral immunity, or for
protein delivery in prime-boost combinations with viral
vectors, particle-mediated delivery is an attractive option
to efficiently and safely enhance immune responses to
protein-based vaccines.
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